A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers (NCT04262466)
IMC-F106C-101
This trial is No longer recruiting
Registration number NCT04262466
Program & service
This trial is being run with the Cancer service, and as part of the Medical Oncology program.
Trial phase
Phase 1
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Mark Voskoboynik
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR